Novo Nordisk A/S (NVO) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on Novo Nordisk A/S (NVO) is Neutral.

The composite score behind that read is +0.18, weighing +0.52 of bullish evidence against -0.34 bearish.

Novo Nordisk A/S last closed at $38.64, +1.20% on the session.

Against the IVW growth benchmark the position is +0.40% over the forecast window.

The read is built from 15 underlying insights — 9 bullish and 6 bearish.

Agreement across those insights is 60%.

Novo Nordisk A/S has no graded predictions yet. We publish our accuracy across thousands of stocks in the open, misses included.

On the fundamentals StockMap ranks Novo Nordisk A/S in the 86th percentile on valuation and the 93rd percentile on return on equity, where 100 is best.

Novo Nordisk A/S is classified under Health Care / Pharmaceuticals, with a market capitalisation of $127.93B.

StockMap tracks Novo Nordisk A/S as the 7th largest of the 151 companies it covers in the Pharmaceuticals industry, part of the Health Care sector.

Across that group the current two-week reads are 90 Neutral, 46 Moderate Underperform and 15 Moderate Outperform.

On that composite Novo Nordisk A/S ranks 18th of 151 in the group, against a group median of -0.08.